Penserra Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3K | Hold |
48
| – | – | ﹤0.01% | 968 |
|
|
2025
Q4 | $4K | Hold |
48
| – | – | ﹤0.01% | 921 |
|
|
2025
Q3 | $3K | Sell |
48
-3
| -6% | -$234 | ﹤0.01% | 919 |
|
|
2025
Q2 | $3K | Hold |
51
| – | – | ﹤0.01% | 907 |
|
|
2025
Q1 | $3K | Sell |
51
-1,495
| -97% | -$107K | ﹤0.01% | 952 |
|
|
2024
Q4 | $113K | Buy |
1,546
+1,495
| +2,931% | +$105K | ﹤0.01% | 828 |
|
|
2024
Q3 | $3K | Buy |
51
+3
| +6% | +$218 | ﹤0.01% | 972 |
|
|
2024
Q2 | $4K | Hold |
48
| – | – | ﹤0.01% | 1077 |
|
|
2024
Q1 | $4K | Sell |
48
-2,757
| -98% | -$232K | ﹤0.01% | 1076 |
|
|
2023
Q4 | $213K | Sell |
2,805
-601
| -18% | -$41.8K | ﹤0.01% | 722 |
|
|
2023
Q3 | $235K | Sell |
3,406
-523
| -13% | -$42K | ﹤0.01% | 689 |
|
|
2023
Q2 | $370K | Buy |
3,929
+3,895
| +11,456% | +$339K | 0.01% | 621 |
|
|
2023
Q1 | $2K | Hold |
34
| – | – | ﹤0.01% | 989 |
|
|
2022
Q4 | $2K | Buy |
+34
| New | +$2.62K | ﹤0.01% | 1047 |
|
|
2020
Q4 | – | Sell |
-972
| Closed | -$77K | – | 1047 |
|
|
2020
Q3 | $77K | Buy |
+972
| New | +$75.8K | ﹤0.01% | 571 |
|
|
2020
Q2 | – | Sell |
-81,804
| Closed | -$5.14M | – | 836 |
|
|
2020
Q1 | $5.14M | Buy |
+81,804
| New | +$5.9M | 0.35% | 98 |
|
|
2019
Q4 | – | Sell |
-148,389
| Closed | -$10.9M | – | 903 |
|
|
2019
Q3 | $10.9M | Buy |
+148,389
| New | +$10.4M | 0.92% | 21 |
|
|
2019
Q1 | – | Sell |
-144,876
| Closed | -$7.4M | – | 738 |
|
|
2018
Q4 | $7.4M | Buy |
144,876
+136,044
| +1,540% | +$6.88M | 0.72% | 52 |
|
|
2018
Q3 | $512K | Buy |
8,832
+1,248
| +16% | +$61K | 0.03% | 282 |
|
|
2018
Q2 | $368K | Sell |
7,584
-38,295
| -83% | -$1.79M | 0.02% | 254 |
|
|
2018
Q1 | $2.13M | Buy |
45,879
+39,159
| +583% | +$1.7M | 0.2% | 81 |
|
|
2017
Q4 | $252K | Buy |
6,720
+1,056
| +19% | +$38.8K | 0.03% | 208 |
|
|
2017
Q3 | $207K | Buy |
5,664
+672
| +13% | +$25.6K | 0.05% | 191 |
|
|
2017
Q2 | $196K | Buy |
4,992
+576
| +13% | +$21K | 0.07% | 206 |
|
|
2017
Q1 | $138K | Sell |
4,416
-285
| -6% | -$8.92K | 0.01% | 269 |
|
|
2016
Q4 | $145K | Sell |
4,701
-28,395
| -86% | -$920K | 0.02% | 276 |
|
|
2016
Q3 | $1.33M | Sell |
33,096
-813
| -2% | -$30.6K | 0.16% | 33 |
|
|
2016
Q2 | $1.13M | Buy |
33,909
+17,436
| +106% | +$597K | 0.16% | 48 |
|
|
2016
Q1 | $483 | Sell |
16,473
-8,229
| -33% | -$227K | 0.05% | 85 |
|
|
2015
Q4 | $650K | Buy |
+24,702
| New | +$641K | 0.06% | 109 |
|
Other funds holding EW
VCM
VPM
Penserra Capital Management's EW Position: Q1 2026 in Review
Penserra Capital Management held its Edwards Lifesciences (EW) position steady in Q1 2026 at 48 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #968.
Penserra Capital Management first reported a position in EW in Q4 2015 and has held it in 30 quarters since. The position peaked at $10.9M in Q3 2019. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Penserra Capital Management held 48 shares of Edwards Lifesciences worth $3K as of Q1 2026.
- Penserra Capital Management left its Edwards Lifesciences share count unchanged in Q1 2026.
- Edwards Lifesciences made up ﹤0.01% of Penserra Capital Management's portfolio in Q1 2026, its #968 holding.
- Penserra Capital Management first reported a position in Edwards Lifesciences in Q4 2015 and has held it in 30 quarters since.
- Penserra Capital Management's Edwards Lifesciences position peaked at $10.9M in Q3 2019.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.